60 results on '"Horan, Martin"'
Search Results
2. Supplementary Figure 6 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
3. Supplementary Figure 2 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
4. Supplementary Figure 9 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
5. Data from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
6. Supplementary Figure 9 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
7. Supplementary Figure 2 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
8. Supplementary Figure 5 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
9. Supplementary Figure 10 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
10. Supplementary Figure 8 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
11. Supplementary Figure 10 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
12. Supplementary Table 1 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
13. Supplementary Figure Legends 1-10 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
14. Supplementary Figure 5 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
15. Supplementary Figure 1 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
16. Supplementary Methods for Figure 1 and Table 1 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
17. Data from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
18. Supplementary Figure 6 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
19. Supplementary Figure 1 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
20. Supplementary Table 1 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
21. Supplementary Figure 8 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
22. Supplementary Figure 4 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
23. Supplementary Methods for Figure 1 and Table 1 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
24. Supplementary Figure 4 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
25. Supplementary Figure Legends 1-10 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
26. Supplementary Figure 7 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
27. Supplementary Figure 7 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
28. Supplementary Figure 3 from Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
29. Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative
30. Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path)
31. External Quality Assurance of Current Technology for the Testing of Cancer-Associated Circulating Free DNA Variants
32. From Somatic Variants Toward Precision Oncology: An Investigation of Reporting Practice for Next‐Generation Sequencing‐Based Circulating Tumor DNA Analysis
33. An external quality assurance trial to assess mass spectrometry protein testing facilities for identifying multiple human peptides
34. RCPAQAP Update: Quality Assurance In Maternal Cell Contamination
35. High rates of variation in HLA-DQ2/DQ8 testing for coeliac disease: results from an RCPAQAP pilot program
36. Developing a quantitative external quality assurance (EQA) module to monitor BCR-ABL1 levels in chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) using the international scale (IS) to determine a patient's molecular response
37. Developing quality assurance program for total DNA extraction
38. Developing a quality assurance program on the detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC)
39. Quality assurance for next generation sequencing
40. The Influence of Macronutrients on Splanchnic and Hepatic Lymphocytes in Aging Mice
41. The emergence of the mitochondrial genome as a partial regulator of nuclear function is providing new insights into the genetic mechanisms underlying age-related complex disease
42. Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts
43. Alpha-Synuclein Transmission and Mitochondrial Toxicity in Primary Human Foetal Enteric Neurons In Vitro
44. From evolutionary bystander to master manipulator: the emerging roles for the mitochondrial genome as a modulator of nuclear gene expression
45. Quaternary protein modeling to predict the function of DNA variation found in human mitochondrial cytochrome c oxidase
46. Application of Chromosome Conformation Capture (3C) to the Study of Human Genetic Disease
47. Review: Quantifying Mitochondrial Dysfunction in Complex Diseases of Aging
48. Methylation-mediated Transcriptional Silencing in Tumorigenesis
49. Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
50. Characterisation of a functional intronic polymorphism in the human growth hormone (GHI) gene
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.